Erectile dysfunction (ED) affects millions of men worldwide, impacting quality of life and intimate relationships. Among the many treatments available, Malegra Oral Jelly, a fast-acting sildenafil-based therapy, has gained popularity for its convenience and effectiveness. However, not all men respond equally well to this medication. Recent advances in medical research point to the growing importance of biomarkers—biological indicators that can predict how well a patient might respond to treatment.